Publication | Closed Access

IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial

Rheumatoid DisorderRheumatologyChronic Musculoskeletal ConditionClinical TrialsPsoriatic ArthritisEquivalence TrialMedicineAxial SpondyloarthritisOrthopaedic SurgeryRheumatoid Arthritis